What is Arecor?
Arecor operates at the intersection of advanced biopharmaceutical research and drug delivery engineering. Its core value proposition centers on the Arestat technology platform, which enables the development of superior therapeutic formulations for diabetes and obesity. By focusing on the stabilization of proteins and peptides, Arecor addresses significant unmet needs in the treatment of chronic cardiometabolic conditions. The company's business model is characterized by strategic partnerships with established pharmaceutical entities, allowing it to monetize its innovative delivery mechanisms while maintaining a robust pipeline of proprietary assets. This dual-track approach ensures both immediate commercial relevance and long-term scientific impact in the highly competitive life sciences sector.
How much funding has Arecor raised?
Arecor has raised a total of $8M across 2 funding rounds:
Private Equity
$230K
Unspecified
$7.8M
Private Equity (2015): $230K with participation from Hygea VCT Plc
Unspecified (2018): $7.8M led by Albion Capital Group, Calculus Capital, and Downing
Key Investors in Arecor
Albion Capital Group
AlbionVC is the technology investment arm of Albion Capital Group LLP, managing approximately 1 billion in venture funds and supporting visionary founders with long-term capital and scale-up expertise.
Calculus Capital
Calculus Capital is a London-based investment manager specializing in tax-efficient growth capital for UK smaller companies, focusing on high-growth technology and healthcare businesses.
Downing
Founded in 1986, Downing is a London-based financial services firm that designs and manages diverse investment products, providing essential capital to growing enterprises.
What's next for Arecor?
With the capital secured through its recent financing rounds, Arecor is well-positioned to transition its lead candidates through advanced clinical trials and further validate the versatility of the Arestat platform. The strategic focus will likely shift toward scaling manufacturing capabilities and deepening its collaborative pipeline with global medtech leaders. As the company matures, the emphasis will remain on navigating regulatory pathways and securing additional intellectual property protections to maintain its competitive edge. Investors and industry stakeholders will be monitoring the company's ability to translate its technical milestones into commercialized therapeutic solutions, which remains the primary catalyst for future valuation growth in the biopharmaceutical space.
See full Arecor company page
